<DOC>
	<DOC>NCT02919449</DOC>
	<brief_summary>This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with nivolumab in patients with recurrent and metastatic (NSCLC).</brief_summary>
	<brief_title>Trial of Measles Virotherapy in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intratumoral injection of MVNIS. Patient meets the FDAapproved indication for nivolumab treatment in NSCLC. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. Ability to provide informed consent. Adequate hematological, liver and kidney function. Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration. Key Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration Other concurrent investigational therapy (utilized for a nonFDAapproved indication and in the context of a research investigation). Pregnant women. Nursing women. Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment. Allergy to measles vaccine or history of severe reaction to prior measles vaccination. History of organ transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lung Cancer Measles Nivolumab Opdivo</keyword>
</DOC>